

Late-stage Development Pipeline

Phase III

Avastin <ul style="list-style-type: none"> Adjuvant colon cancer Adjuvant HER2-negative breast cancer Adjuvant HER2-positive breast cancer Adjuvant non-small cell lung cancer Diffuse large B-cell lymphoma First-line advanced gastric cancer First-line HER2-negative metastatic breast cancer First-line HER2-positive metastatic breast cancer First-line metastatic ovarian cancer Gastrointestinal stromal tumors High risk carcinoid Hormone refractory prostate cancer Newly diagnosed glioblastoma multiforme¹ Metastatic head and neck cancer¹ Relapsed platinum-sensitive ovarian cancer Second-line metastatic breast cancer 	Ocrelizumab² <ul style="list-style-type: none"> Lupus nephritis Rheumatoid arthritis
Avastin +/- Tarceva <ul style="list-style-type: none"> First-line metastatic non-squamous, non-small cell lung cancer 	Pertuzumab <ul style="list-style-type: none"> First-line HER2-positive metastatic breast cancer
Herceptin <ul style="list-style-type: none"> Adjuvant HER2-positive breast cancer (HERA 2-year) 	Rituxan (Hematology/Oncology) <ul style="list-style-type: none"> Follicular non-Hodgkin's lymphoma Relapsed chronic lymphocytic leukemia
Lucentis <ul style="list-style-type: none"> Diabetic macular edema Retinal vein occlusion 	Rituxan (Immunology) <ul style="list-style-type: none"> Active rheumatoid arthritis ANCA-associated vasculitis Lupus nephritis
	Tarceva <ul style="list-style-type: none"> Adjuvant non-small cell lung cancer First-line metastatic non-small cell lung cancer
	TNKase <ul style="list-style-type: none"> Central venous catheter clearance Hemodialysis catheter clearance
	Trastuzumab-DM1 <ul style="list-style-type: none"> Second-line HER2-positive metastatic breast cancer¹
	Xolair <ul style="list-style-type: none"> Asthma

FDA Submission Prep

Avastin <ul style="list-style-type: none"> Relapsed glioblastoma multiforme
Xolair <ul style="list-style-type: none"> Pediatric asthma

Awaiting FDA Action

Avastin <ul style="list-style-type: none"> First-line metastatic renal cell carcinoma
Rituxan <ul style="list-style-type: none"> Rheumatoid arthritis DMARD-inadequate responders

Legend

- Immunology
- Oncology
- Tissue Growth & Repair

As of October 14, 2008

- Preparing for phase.
- Our collaborator Biogen Idec disagrees with certain of our development decisions under our 2003 collaboration agreement. We continue to pursue a resolution of our differences with Biogen Idec. The disputed issues were submitted to arbitration in San Francisco, California and a hearing was held in September 2008 with a concluding hearing to take place in December 2008. We expect that we will receive a ruling by approximately June 2009. The arbitration proceedings with Biogen Idec are confidential and we will not provide details on the program disagreements with Biogen Idec nor the hearing discussions.

ANCA = Anti-Neutrophilic Cytoplasmic Antibodies; DMARD = Disease-Modifying Anti-Rheumatic Drugs.